Alvotech Reports First Half Financial Results
Biotechnology company Alvotech (NASDAQ:ALVO) reported first-half financial results, showing an adjusted EBITDA of $46.9 million for the period compared to $53.7 million in the same time last year. Revenue declined by 30.8% year-over-year to $211.9 million. The company also announced a new $75 million term loan facility, which is expected to enhance its capital access and support ongoing operations or expansion initiatives. Alvotech has been active in presenting at major industry conferences such as the UBS Virtual Generics and Biosimilars Day and Goldman Sachs' Global Healthcare Conference. Despite challenges highlighted by a speculative 'Buy' recommendation amid FDA CMC requirements, the firm continues to engage with investors through earnings previews and conference appearances.
Topics: adjusted_ebitda biotech revenue_decline